Drug-drug interactions are an important consideration in drug development. Human hepatocytes are used for the evaluation of gene induction of drug-metabolizing enzymes after exposure to drugs. [1] [2] [3] [4] [5] [6] [7] We previously reported a method for evaluating the gene induction of drug-metabolizing enzymes and transporters after exposure to model drugs such as rifampicin and omeprazole in primary culture of human hepatocytes. 8) It has been suggested that UGT1A6 and UGT1A9 are inducible by aryl hydrocarbon receptor agonists. 9) ABCB1 encodes for P-glycoprotein, which transports numerous neutral and cationic compounds out of many types of cells. 10) Generally, the drugs are dissolved in water-miscible organic solvents such as dimethyl sulfoxide (DMSO) for in vitro induction studies. Rifampicin is a potent inducer of CYP3A in primary culture of human hepatocytes, 2,3) and bnaphthoflavone is a potent inducer of CYP1A in primary culture of human hepatocytes. 5) We therefore investigated the effects of exposure to DMSO on the gene expression of drugmetabolizing enzymes (CYPs, UGTs, and ABCB1) in primary culture of human hepatocytes. Further, we investigated the effects of exposure to model drugs such as b-naphthoflavone and rifampicin on gene induction in the CYP1 and CYP3A subfamilies, respectively, at various DMSO concentrations. Covers, and Optical Cover Compression Pads were purchased from Applied Biosystems (Foster City, CA, U.S.A.). All other chemicals and reagents used were of analytical reagent grade.
human epidermal growth factor (hEGF), gentamicin, or amphotericin B, and the cells were cultured for 24 h under 5% CO 2 and 95% air at 37°C. The cells were used for experiments at 48 h after inoculation.
Experiments Using Monolayer Cultures of Hepatocytes After 48 h of inoculation, the human hepatocytes were treated with a number of known inducers for an additional 24 h. During treatment, the hepatocytes were cultured without hEGF, gentamicin, or amphotericin B under 5% CO 2 and 95% air at 37°C. The effects of DMSO were evaluated at DMSO concentrations of 0.1%, 0.5%, and 2.5% (v/v) and in DMSO-free controls. The effects of b-naphthoflavone were studied at a concentration of 5 mM, and the effects of rifampicin were studied at a concentration of 10 mM. All inducers were dissolved in DMSO to final vehicle concentrations of 0.1%, 0.5%, and 2.5%. Controls with treated cells were included in the experimental design in order to assess mRNA expression relative to controls at each DMSO concentration. Total RNA was extracted from the hepatocytes using the Rneasy ® Mini Kit and QIAshredder TM .
Oligonucleotides The pairs of forward and reverse primers and the TaqMan probes for CYP1A1 (GenBank accession number NM_000499), CYP1A2 (AF182274), CYP1B1 (NM_000104), CYP2A6 (AF182275), CYP2E1 (AF182276), CYP3A4 (AF182273), CYP3A5 (NM_000777), UGT1A6 (NM_001072), UGT1A9 (AF056188), and ABCB1 (NM_000927) used in the RT-PCR sequences employed have been reported previously. 8) The pair of primers and the TaqMan probe for CYP3A7 were designed using Primer Express software (Applied Biosystems) to amplify a 198-base-pair fragment of the human CYP3A7 mRNA sequence (GenBank accession number NM_000765). Each primer and/or probe was homology searched by an NCBI BLAST search to ensure that it was specific for the target mRNA transcript. The pair of primers and the TaqMan probe for CYP3A7 are shown below together with the position from the initiation codon: The primers and TaqMan probes were synthesized by Sawady Technology Co., Ltd. (Tokyo, Japan). The TaqMan probes contained 6-carboxyfluorescein (FAM) at the 5Ј end and 6-carboxytetramethylrhodamine (TAMRA) at the 3Ј end and were designed to hybridize to a sequence located between the PCR primers. Statistical Analysis Analysis of the data was performed with the ABI PRISM sequence detection software. The relative expression of each mRNA was calculated by the DCt (the value obtained by subtracting the Ct value of b-actin mRNA from the Ct value of the target mRNA) method, which has been generally employed in such real-time RT-PCR analysis. 11, 12) Specifically, the amount of target relative to b-actin mRNA was expressed as 2 Ϫ(DCt) . Data are expressed as the ratio of target mRNA to b-actin mRNA. Further, the values indicate results relative to control. Experiments on the effects of culture on GAPDH and CYP3A4 mRNA expression in donor 2 using human hepatocyte cultures were performed in triplicate, and results for the ratio of target mRNA to b-actin mRNA are shown as meanϮS.D. Other experiments involving human hepatocyte cultures were performed in duplicate, and the results relative to controls are shown as mean values.
RESULTS AND DISCUSSION
Direct sequencing of human liver QUICK-Clone cDNA PCR products unequivocally yielded the expected sequences from the respective amplification products (data not shown). Further, the use of a TaqMan probe increased the level of specificity of the assay. The TaqMan method was found to be exquisitely specific and to permit quantitative evaluation, with the limit of quantification 2 times higher or lower than in controls. Figure 1 shows the mRNA expression data for GAPDH and CYP3A4 in cultured human hepatocytes. b-actin was used as the endogenous control in the measurement of target mRNAs. Specifically, the ratio of GAPDH, as a housekeeping gene, to b-actin decreased to 20% of the initial level during the first 24 h, after which the ratio remained constant (Fig. 1A) . The present method was found to be applicable to the evaluation of enzyme induction after the first 48 h of culture. Bowen et al. 1) compared the initial expression levels of CYP3A4 mRNA with those on day 5 of culture using cultured human hepatocytes and found that CYP3A4 mRNA expression decreased to 1% of the initial level. Similarly, Fig.  1B shows that CYP3A4 mRNA expression decreased to 0.13% of the initial level after 72-h culture.
In the present study, we investigated the gene expression of GAPDH, cytochrome P450 isoforms (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2E1, CYP3A4, CYP3A5, and CYP3A7), UGT-dependent glucuronosyl transferase isoforms (UGT1A6 and UGT1A9), and ABC transporter (ABCB1) after exposure to 0.1%, 0.5%, and 2.5% DMSO. Expression data are shown in Fig. 2 . Data are expressed as the ratio of target mRNA to b-actin mRNA, and data are then given as values relative to controls without DMSO. The ratio of target mRNA to b-actin mRNA was 1.5 times lower at both levels in duplicate runs at all DMSO concentrations (data not shown). The expression levels in controls without DMSO are also shown as the ratios of GAPDH mRNA and target mRNA to b-actin mRNA ( Table 2 ). The C.V. value of GAPDH mRNA was 29.8%, and little difference was observed among the 3 donors. The C.V. values of the target (CYPs, UGTs, and ABCB1) mRNAs were 24.0 to 110.0%. None of the treatments were associated with any identifiable toxic effects such as cell death or loss of adhesion of hepatocytes, as assessed by microscopic examination, at the concentrations employed in this study. GAPDH mRNA levels after exposure were less than 2 times higher or lower than control levels at all DMSO concentrations ( Fig. 2A ). Therefore, it is considered that the expression of both GAPDH and b-actin mRNA after exposure at all DMSO concentrations did not change to the levels in controls. CYP1A1, CYP1B1, CYP2A6, CYP2E1, CYP3A4, CYP3A5, CYP3A7, and UGT1A9 mRNA levels were less than 2 times higher or lower than control levels at 0.1% and 0.5% DMSO (Fig. 2B , D-I, K). The CYP1A1 mRNA level for donor 1 was increased 2.5 fold at 2.5% DMSO (Fig. 2B ). CYP1B1 mRNA levels for donors 1 and 3 were increased 2.0 and 3.0 fold, respectively, at 2.5% DMSO (Fig. 2D) . The CYP2A6 mRNA level for donor 2 was increased 2.4 fold at 2.5% DMSO (Fig.  2E) . The CYP3A5 mRNA level for donor 1 was increased 2.0 fold at 2.5% DMSO (Fig. 2H ). CYP3A7 mRNA levels for donors 1 and 2 were 0.5 and 0.4 times lower than control levels, respectively, at 2.5% DMSO (Fig. 2I ). CYP2E1 mRNA levels were 2.5 to 3.2 times higher than control levels at 2.5% DMSO (Fig. 2F ). CYP3A4 mRNA levels were 2.0 to 3.3 times higher than control levels at 2.5% DMSO (Fig.  2G ). UGT1A9 mRNA levels were 0.2 to 0.5 times lower than control levels at 2.5% DMSO (Fig. 2K ). CYP1A2, UGT1A6, and ABCB1 mRNA levels were less than 2 times higher or lower than control levels at all DMSO concentrations (Fig.  2C, J, L) .
In the experiment at 0.1% DMSO for donor 2, exposure to b-naphthoflavone increased the levels of CYP1A1 and CYP1A2 mRNA in a concentration-dependent manner to 5 mM, and exposure to rifampicin increased the level of CYP3A4 mRNA in a concentration-dependent manner to 10 mM. Therefore, in the present study, the concentrations of b-naphthoflavone and rifampicin used were 5 mM and 10 mM, respectively. GAPDH mRNA levels, which were normalized to b-actin mRNA, after exposure to b-naphthoflavone and rifampicin were less than 2 times higher or lower than control levels (data not shown). Therefore, it is considered that the expression of both GAPDH and b-actin mRNA after exposure to b-naphthoflavone and rifampicin did not change to the levels in controls. Figure 3 shows mRNA expression levels following exposure to 5 mM b-naphthoflavone at various DMSO concentrations. Exposure to b-naphthoflavone reduced CYP1A1 mRNA levels in a concentration-dependent manner for donors 1 and 2 (Fig. 3A) . Exposure to b-naphthoflavone reduced CYP1A2 mRNA levels in a concentration-dependent manner for all donors (Fig. 3B ). On the other hand, exposure to b-naphthoflavone increased CYP1B1 mRNA levels for donors 2 and 3 at 2.5% DMSO (Fig. 3C) . The individual differences observed in the expression profiles of CYP1A1, CYP1B1, etc. may reflect differences in the sensitivity of the hepatocytes from each donor to DMSO. Figure  4 shows mRNA expression levels following exposure to 10 mM rifampicin at various DMSO concentrations. Exposure to rifampicin reduced CYP3A4 mRNA levels for all donors at 0.5% and 2.5% DMSO (Fig. 4A ). Exposure to rifampicin also reduced CYP3A5 and CYP3A7 mRNA levels for donors 1 and 3 at 0.5% and 2.5% DMSO (Fig. 4B, C) . The mechanisms by which DMSO decreased the expression of CYP1A and CYP3A mRNA and increased the expression of CYP1B1 mRNA are not clear. However, it is possible that the decrease in the induction ratio of CYP1A and CYP3A mRNA at high DMSO concentrations may be due to the low intracellular concentration of the drug followed by a decrease in the influx and/or an increase in the efflux of the drug as an effect of DMSO. It is possible that the increase in the induction ratio of CYP1B1 mRNA may be related to a synergistic effect between DMSO and the drug. Therefore, the induction of CYP1A and CYP3A mRNA after drug exposure may be underestimated at high DMSO concentrations. On the other hand, the induction of CYP1B1 mRNA after drug exposure may be overestimated at high DMSO concentrations. Zangar and Novak reported that phenobarbital treatment of primary cultured rat hepatocytes in the presence of DMSO at a concentration of 0.1% or less had no significant effect on CYP3A and CYP2B mRNA levels, but that a significant de- crease in CYP3A and CYP2B mRNA levels was observed in phenobarbital-treated primary cultured rat hepatocytes following treatment with 1% or 2% DMSO. 13) Because of its ability to dissolve a large number of organic chemicals, DMSO is usually the solvent of choice in such studies. The evaluation of induction after exposure to drugs in the pres-ence of DMSO at a concentration of 0.1% or less in primary cultured human hepatocytes has been reported. [3] [4] [5] [6] [14] [15] [16] In conclusion, our findings with regard to human hepatocytes and the results of other reports indicate that it is important to evaluate the effects of drug exposure at low DMSO concentrations. A DMSO concentration of 0.1% or less may be appropriate for the study of induction after exposure to drugs. Fig. 3 . Effects on mRNA Expression Levels Following Exposure to 5 mM b-Naphthoflavone in the Presence of DMSO at Concentrations of 0.1, 0.5, and 2.5% Human hepatocytes were treated with b-naphthoflavone for 24 h. Data are expressed as the ratio of target mRNA to b-actin mRNA, and data are then given as the ratio to controls at each DMSO concentration. Experiments (in cultured human hepatocytes) were performed in duplicate, and data are shown as mean values. A: CYP1A1; B: CYP1A2; C: CYP1B1. Fig. 4 . Effects on mRNA Expression Levels Following Exposure to 10 mM Rifampicin in the Presence of DMSO at Concentrations of 0.1, 0.5, and 2.5% Human hepatocytes were treated with rifampicin for 24 h. Data are expressed as the ratio of target mRNA to b-actin mRNA, and data are then given as the ratio to controls at each DMSO concentration. Experiments (in cultured human hepatocytes) were performed in duplicate, and data are shown as mean values. A: CYP3A4; B: CYP3A5; C: CYP3A7.
